Agendia is a world leader in gene expression analysis-based diagnostics. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first to commercialize a prognostic test - MammaPrint® - that predicts the chance of breast cancer recurrence. Recently Agendia also added CupPrint® to its pipeline for the identification of Cancers of Unknown Primary. Agendia maintains close ties with the Netherlands Cancer Institute (NKI), ensuring access to the latest developments in cancer research. Apart from the development of new cancer diagnostics, Agendia offers its expertise in finding new predictive gene expression profiles to companies focusing on new drug development in the area of oncology.